A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Arhalofenate (MBX-102) in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout.

Trial Profile

A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Arhalofenate (MBX-102) in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2015

At a glance

  • Drugs Arhalofenate; Febuxostat
  • Indications Gout
  • Focus Therapeutic Use
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 08 Dec 2011 Results have been reported in a Metabolex media release.
    • 08 Dec 2011 Primary endpoint 'Response-rate' has been met.
    • 20 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top